Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the activity and tolerability of pazopanib in
subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following
standard therapies or for whom no standard therapy exists and to characterize the
pharmacokinetics of pazopanib in this subject population.